Literature DB >> 11070335

Effects of dexamethasone on cytokine plasma levels and white blood cell counts in depressed patients.

A Schuld1, T Kraus, M Haack, D Hinze-Selch, A W Zobel, F Holsboer, T Pollmächer.   

Abstract

In major depression, alterations of some aspects of the host defense system and the hypothalamo-pituitary-adrenal (HPA) system have been reported. Both systems are closely related, but their interaction in major depression has not yet been explored. Moreover, little is known about the effects of glucocorticoids on the circulating amounts of cytokines in humans in the absence of immunological challenges. Therefore, we investigated the effects of dexamethasone (DEX) in 17 depressed patients who underwent a combined DEX-suppression and corticotropine-releasing-hormone (CRH)-stimulation test on white blood cell counts, and on the plasma levels of granulocyte colony-stimulating factor (G-CSF), interleukin (IL)-6, IL-10, tumor necrosis factor (TNF)-alpha, and soluble TNF-receptors (sTNF-R) p55 and p75. DEX induced an increase in granulocyte counts, which was positively correlated with increases in the circulating amounts of G-CSF and paralleled by decreased lymphocyte and monocyte counts. Moreover, DEX reduced the plasma levels of IL-6, TNF-alpha and sTNF-R p75. The levels of sTNF-R p55 and IL-10 were not affected. DEX-induced changes in immunological parameters did not differ between patients who had different amounts of HPA-system alteration, and were neither related to the severity of depressive symptomatology or to other clinical features. We conclude that a single oral dose of DEX, even in the absence of infection and inflammation, affects the circulating amounts of cytokines and soluble cytokine receptors, further supporting the pivotal role of these immune-mediators in glucocorticoid-induced immunomodulation. Neuroendocrinological alterations associated with major depression seem to be independent from these processes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11070335     DOI: 10.1016/s0306-4530(00)00039-1

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  5 in total

1.  Aspirin-Triggered Resolvin D1 Versus Dexamethasone in the Treatment of Sjögren's Syndrome-Like NOD/ShiLtJ Mice - A Pilot Study.

Authors:  Justin T Easley; Joel W Nelson; Rachel E Mellas; Salah Sommakia; Chunhua Wu; Bryan Trump; Olga J Baker
Journal:  J Rheum Dis Treat       Date:  2015-12-17

2.  Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema.

Authors:  Cameron J Herting; Zhihong Chen; Victor Maximov; Alyssa Duffy; Frank Szulzewsky; Dmitry M Shayakhmetov; Dolores Hambardzumyan
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

3.  Granulocyte colony-stimulating factor blockade enables dexamethasone to inhibit lipopolysaccharide-induced murine lung neutrophils.

Authors:  Jesus Banuelos; Yun Cao; Soon Cheon Shin; Bruce S Bochner; Pedro Avila; Shihong Li; Xin Jiang; Mark W Lingen; Robert P Schleimer; Nick Z Lu
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240

4.  Monocytes carrying GFAP detect glioma, brain metastasis and ischaemic stroke, and predict glioblastoma survival.

Authors:  Wouter B L van den Bossche; Arnaud J P E Vincent; Cristina Teodosio; Jeroen Koets; Aladdin Taha; Anne Kleijn; Sandra de Bruin; Willem A Dik; Daniela Damasceno; Julia Almeida; Diederik W J Dippel; Clemens M F Dirven; Alberto Orfao; Martine L M Lamfers; Jacques J M van Dongen
Journal:  Brain Commun       Date:  2020-12-26

5.  Dexamethasone Protects Against Tourniquet-Induced Acute Ischemia-Reperfusion Injury in Mouse Hindlimb.

Authors:  Ryan M Corrick; Huiyin Tu; Dongze Zhang; Aaron N Barksdale; Robert L Muelleman; Michael C Wadman; Yu-Long Li
Journal:  Front Physiol       Date:  2018-03-20       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.